Head to Head Contrast: Processa Pharmaceuticals (NASDAQ:PCSA) vs. Oncternal Therapeutics (NASDAQ:ONCT)

Share on StockTwits

Processa Pharmaceuticals (NASDAQ:PCSA) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Processa Pharmaceuticals and Oncternal Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Processa Pharmaceuticals N/A N/A -$3.36 million N/A N/A
Oncternal Therapeutics $2.42 million 26.50 -$34.19 million ($1.56) -1.84

Processa Pharmaceuticals has higher earnings, but lower revenue than Oncternal Therapeutics.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Processa Pharmaceuticals and Oncternal Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Processa Pharmaceuticals 0 0 1 0 3.00
Oncternal Therapeutics 0 0 1 0 3.00

Oncternal Therapeutics has a consensus target price of $8.00, indicating a potential upside of 178.75%. Given Oncternal Therapeutics’ higher probable upside, analysts clearly believe Oncternal Therapeutics is more favorable than Processa Pharmaceuticals.

Insider & Institutional Ownership

13.6% of Oncternal Therapeutics shares are owned by institutional investors. 54.6% of Processa Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Oncternal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Processa Pharmaceuticals and Oncternal Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Processa Pharmaceuticals N/A -42.54% -31.11%
Oncternal Therapeutics -778.45% -147.33% -92.60%

Volatility & Risk

Processa Pharmaceuticals has a beta of -0.76, indicating that its share price is 176% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.

Summary

Processa Pharmaceuticals beats Oncternal Therapeutics on 5 of the 9 factors compared between the two stocks.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It also has license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was founded in 2015 and is based in Hanover, Maryland.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.

Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Glenn Molloy Acquires 37,035 Shares of PPK Group Limited   Stock
Glenn Molloy Acquires 37,035 Shares of PPK Group Limited Stock
Intact Financial   Shares Down 1.8%
Intact Financial Shares Down 1.8%
Dexus  Trading 2.9% Higher
Dexus Trading 2.9% Higher
Beam Global  Receives Buy Rating from Maxim Group
Beam Global Receives Buy Rating from Maxim Group
Reviewing TriMas  & Stamford Industrial Group
Reviewing TriMas & Stamford Industrial Group
Morgan Stanley Increases Autodesk  Price Target to $266.00
Morgan Stanley Increases Autodesk Price Target to $266.00


 
© 2006-2020 Zolmax.